DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE
Clinical safety rating
safeOther antihypertensive drugs can have additive effects Can cause retrograde ejaculation and orthostatic hypotension.
Dutasteride inhibits both type 1 and type 2 isoforms of 5α-reductase, preventing conversion of testosterone to dihydrotestosterone (DHT), reducing prostate volume. Tamsulosin is a selective antagonist of alpha-1A and alpha-1D adrenoceptors, relaxing smooth muscle in the prostate and bladder neck.
| Metabolism | Dutasteride is extensively metabolized by CYP3A4 and CYP3A5; tamsulosin is primarily metabolized by CYP2D6 and to a lesser extent by CYP3A4. |
| Excretion | Dutasteride: 40% as metabolites in feces (mainly via bile), 5% in urine. Tamsulosin: 76% in urine as unchanged drug and metabolites, 24% in feces. |
| Half-life | Dutasteride: Terminal half-life ~5 weeks (3-7 weeks), allowing once-daily dosing; steady-state reached at 3-6 months. Tamsulosin: Terminal half-life ~9-13 hours in healthy subjects, prolonged in elderly (up to 16-19 hours). |
| Protein binding | Dutasteride: >99.5% bound to albumin and alpha-1-acid glycoprotein. Tamsulosin: 94-99% bound to alpha-1-acid glycoprotein. |
| Volume of Distribution | Dutasteride: Vd 300-500 L (total body, large tissue distribution). Tamsulosin: Vd 0.2 L/kg (approx 14-30 L, moderate distribution). |
| Bioavailability | Dutasteride: Oral bioavailability ~60% (enhanced with food). Tamsulosin: Oral bioavailability ~30% (increased with food; formulation designed for consistent absorption). |
| Onset of Action | Dutasteride: Clinical effect on DHT levels within 1-2 weeks; symptom improvement over 3-6 months. Tamsulosin: Onset of action within 1-2 hours after oral administration. |
| Duration of Action | Dutasteride: Duration of suppression of DHT persists for months after discontinuation due to long half-life. Tamsulosin: Duration of action ~24 hours with once-daily dosing, but maximal effect on urinary flow occurs within 2-6 hours. |
| Molecular Weight | Dutasteride: 528.5 Da; Tamsulosin hydrochloride: 456.9 Da (free base 408.5 Da). For combination product, weight is per component. |
One capsule (dutasteride 0.5 mg / tamsulosin hydrochloride 0.4 mg) orally once daily, approximately 30 minutes after the same meal each day.
| Dosage form | CAPSULE |
| Renal impairment | No dosage adjustment is required for renal impairment. Tamsulosin is extensively metabolized and renally excreted as inactive metabolites; however, no specific GFR-based adjustments are recommended. |
| Liver impairment | Dutasteride is contraindicated in patients with severe hepatic impairment (Child-Pugh Class C). For mild to moderate hepatic impairment (Child-Pugh A or B), no dosage adjustment is recommended, but caution is advised. |
| Pediatric use | Safety and efficacy in pediatric patients have not been established. Use is not recommended in patients under 18 years of age. |
| Geriatric use | No specific dose adjustment is required based on age alone. Elderly patients may be more sensitive to orthostatic hypotension from tamsulosin; monitor blood pressure and advise caution when rising from a seated or lying position. |
| 1st trimester | Dutasteride is contraindicated in pregnancy due to risk of fetal harm (inhibits conversion of testosterone to DHT, potentially affecting male fetal genital development). Tamsulosin is an alpha-1 blocker with limited data; generally avoided unless benefit outweighs risk. Combination product should not be used in women. |
| 2nd trimester | Contraindicated due to shared risks. |
| 3rd trimester | Contraindicated due to shared risks. |
Clinical note
Other antihypertensive drugs can have additive effects Can cause retrograde ejaculation and orthostatic hypotension.
| FDA category | Animal |
| Placental transfer | Dutasteride is expected to cross placenta; animal studies show transfer. Tamsulosin likely crosses; no human data. |
| Breastfeeding | Dutasteride is excreted in human milk; potential for serious adverse effects in nursing infants. Tamsulosin may be excreted in small amounts. Breastfeeding is not recommended during therapy. |
| Lactation Rating | Avoid |
| Teratogenic Risk | Dutasteride is contraindicated in pregnancy due to risk of fetal harm, particularly male genital abnormalities (e.g., hypospadias) from inhibition of dihydrotestosterone. Tamsulosin has no known teratogenic risk. First trimester: Dutasteride exposure may cause feminization of male fetuses. Second and third trimesters: Risk persists; avoid use. |
| Fetal Monitoring | Monitor maternal blood pressure and heart rate for tamsulosin-related orthostatic hypotension. Assess fetal growth and anatomy via ultrasound if inadvertent exposure occurs. No specific monitoring for dutasteride required if pregnancy excluded. |
| Fertility Effects | Dutasteride may reduce semen volume and sperm count due to decreased dihydrotestosterone; effect reversible upon discontinuation. Tamsulosin has no known effects on fertility. |
■ FDA Black Box Warning
None
| Common Effects | Retrograde ejaculation |
| Serious Effects |
PregnancyWomen of childbearing potentialHistory of hypersensitivity to dutasteride, tamsulosin, or any componentUse in pediatric patients
| Precautions | Orthostatic hypotension/syncope, especially with concurrent antihypertensives, Intraoperative floppy iris syndrome during cataract surgery, Risk of high-grade prostate cancer (increased Gleason score 8-10 with dutasteride), Hepatic impairment may increase exposure, Sexual dysfunction: decreased libido, erectile dysfunction, ejaculation disorders |
| Food/Dietary | Absorption of tamsulosin is decreased when taken with food; however, the combination product should be taken 30 minutes after a meal to maintain consistent exposure. Avoid grapefruit juice as it may increase tamsulosin concentrations. No specific food interactions with dutasteride. |
| Clinical Pearls | Dutasteride/tamsulosin is a fixed-dose combination for benign prostatic hyperplasia (BPH). Dutasteride is a 5α-reductase inhibitor that reduces prostate volume over months; tamsulosin is an α1-adrenoceptor antagonist providing rapid symptom relief. Do not split or crush capsules. Avoid use in women and children. Monitor for orthostatic hypotension, especially when initiating therapy. Assess for drug-drug interactions: CYP3A4 inhibitors (e.g., ketoconazole) increase dutasteride exposure; tamsulosin interacts with other α-blockers, antihypertensives, and PDE5 inhibitors. Counsel patients about risk of postural hypotension and syncope. Advise patients to avoid driving or hazardous activities until they know how the medication affects them. Dutasteride may cause sexual dysfunction (decreased libido, ejaculatory dysfunction, gynecomastia). Tamsulosin may cause intraoperative floppy iris syndrome during cataract surgery; inform ophthalmologist of use. Monitor serum PSA levels: dutasteride decreases PSA by ~50% after 6 months; establish new baseline. Do not use in patients with history of prostate cancer. |
| Patient Advice | Take this medication once daily, 30 minutes after the same meal each day. · Swallow capsules whole; do not crush, chew, or open. · Rise slowly from sitting or lying down to avoid dizziness or fainting. · Avoid driving or operating machinery until you know how the drug affects you. · Inform your doctor if you plan to have cataract surgery, as this drug may cause complications. · Do not donate blood while taking this medication, as it may harm a fetus if given to a pregnant woman. · Women who are pregnant or may become pregnant should not handle crushed or broken capsules. · Report any breast lumps, pain, or nipple discharge, as gynecomastia is possible. · Use condoms if your partner is pregnant, as dutasteride can be absorbed through skin contact with semen. · Keep all appointments for PSA blood tests; the test result will be lower than expected. · Do not take other alpha-blocker medications for blood pressure or prostate problems while on this drug unless prescribed. · Grapefruit juice may increase side effects; limit or avoid consumption. · Do not stop taking this medication suddenly without consulting your doctor. |
Loading safety data…